In the present study, we developed a technique for quantification of MART-1 mRNA in RNA from peripheral blood samples.
Data from the analysis of blood samples from patients with malignant melanoma demonstrated the ability of our method to quantify the MART-1 mRNA found in patient samples.
Other mRNA markers (MART-1, MUC18, and p97) have also been shown to have a potential in detecting these cells (7).
MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases.
Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLAA2-restricted recognition of the melanoma antigen Melan-A/ MART-1. Proc Natl Acad Sci U S A 1995;92:5674-8.